tbuckley/cabot-search huggingface dataset:
Familial adversity: association with discontinuation of adjuvant hormone therapy and breast cancer prognosis
Authors: Erwei Zeng, Wei He, Arvid Sjölander, Jenny Bergqvist, Fang Fang, Kamila Czene
Journal: JNCI Journal of the National Cancer Institute (2024)

Abstract Background Many studies have examined patient-related factors affecting adjuvant hormone therapy adherence in patients with breast cancer. Our study aimed to examine associations of family-related factors with adjuvant hormone therapy discontinuation and breast cancer–specific mortality. Methods By cross-linking 7 Swedish health registers, we performed a cohort study that included all patients with breast cancer who initiated adjuvant hormone therapy during 2006-2019 in Sweden (N = 10 701). A group-based multitrajectory model was used to identify familial adversity groups based on 3 dimensions: material deprivation, negative family dynamics, and loss or threat of loss. Cox proportional hazard models were used to investigate associations of familial adversity with hormone therapy discontinuation and breast cancer–specific mortality. Results We identified 5 distinctive familial adversity groups among the cohort participants. Compared with women who had low familial adversity, higher risks to discontinue adjuvant hormone therapy were observed among women with material deprivation (hazard ratio [HR] = 1.31, 95% confidence interval [CI] = 1.20 to 1.43), negative family dynamics (HR = 1.16, 95% CI = 1.06 to 1.28), loss or threat of loss (HR = 1.15, 95% CI = 1.00 to 1.32), or high familial adversity (HR = 1.53, 95% CI = 1.40 to 1.68). Furthermore, women with material deprivation (HR = 1.37, 95% CI = 1.05 to 1.79), negative family dynamics (HR = 1.41, 95% CI = 1.01 to 1.97), or high adversity (HR = 1.67, 95% CI = 1.26 to 2.23) were at higher risk of dying from breast cancer. Conclusion Familial adversity is associated with a higher risk of adjuvant hormone therapy discontinuation and breast cancer–specific mortality. Family-related factors identified in our study may help identify high-risk patients for interventions to prevent treatment discontinuation and subsequently improve breast cancer outcomes.
Potential role of cannabis in ameliorating observed racialized disparities in cancer pain management
Authors: Laurel P Gibson, Rebecca A Ferrer, Salimah H Meghani, Amanda M Acevedo
Journal: JNCI Journal of the National Cancer Institute (2024)

Abstract Cancer-related pain affects a large proportion of all patients with cancer yet remains inadequately managed, particularly among patients from certain racialized backgrounds. Recently, there has been increased research and clinical interest in the use of medical cannabis for cancer pain management, including its potential to ameliorate race-based disparities in cancer pain control. Although medical cannabis is not currently a US Food and Drug Administration–approved treatment option for cancer-related pain, many oncologists discuss and recommend its use with their patients, underscoring the need for researchers and clinicians to proactively identify barriers to cannabis for cancer pain management that may disproportionately affect patients from certain racial groups. In this commentary, we highlight challenges that patients from racialized backgrounds may face when incorporating cannabis into their palliative care regimens and discuss opportunities for researchers and clinicians to address these challenges should medical cannabis become a recommended treatment option for cancer pain management. In particular, we identify challenges at the structural (eg, lack of insurance coverage), clinician (eg, racialized stereotypes regarding addiction and pain), and individual (eg, internalized stigma) levels and emphasize the importance of multilevel approaches in combating these challenges as the evidence base regarding medical cannabis and its potential harms and therapeutic benefits continues to accumulate.
Progressive hyperpigmentation and lentigines due to <i>KIT</i> variants improving with imatinib
Authors: Lina Liang, Sha Peng, Shimiao Huang, Huijun Wang, Zhimiao Lin
Journal: British Journal of Dermatology (2024)

Journal Article Corrected proof Progressive hyperpigmentation and lentigines due to KIT variants improving with imatinib Get access Lina Liang, Lina Liang Data curation, Methodology, Writing - original draft Dermatology Hospital, Southern Medical University, Guangzhou, China Search for other works by this author on: Oxford Academic Google Scholar Sha Peng, Sha Peng Data curation, Investigation, Methodology Dermatology Hospital, Southern Medical University, Guangzhou, China Search for other works by this author on: Oxford Academic Google Scholar Shimiao Huang, Shimiao Huang Data curation Dermatology Hospital, Southern Medical University, Guangzhou, China Search for other works by this author on: Oxford Academic Google Scholar Huijun Wang, Huijun Wang Conceptualization, Funding acquisition, Investigation, Project administration, Supervision Dermatology Hospital, Southern Medical University, Guangzhou, China https://orcid.org/0000-0001-5414-1472 Search for other works by this author on: Oxford Academic Google Scholar Zhimiao Lin Zhimiao Lin Conceptualization, Funding acquisition, Investigation, Project administration, Resources, Supervision, Validation, Writing - review & editing Dermatology Hospital, Southern Medical University, Guangzhou, China Correspondence: Zhimiao Lin. Email: zhimiaolin@bjmu.edu.cn https://orcid.org/0000-0002-3240-1998 Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, ljae109, https://doi.org/10.1093/bjd/ljae109 Published: 12 March 2024 Article history Received: 14 November 2023 Revision received: 04 March 2024 Accepted: 10 March 2024 Published: 12 March 2024 Corrected and typeset: 16 April 2024
Mycosis fungoides: successful re-treatment with brentuximab vedotin
Authors: Mariel James, Mano Nakamura, Sean Whittaker, Stephen Morris
Journal: British Journal of Dermatology (2024)

UK guidelines currently endorse only one course of brentuximab vedotin as second-line treatment for CD30+ CTCL. We demonstrate that re-treatment can be safe, tolerable and highly efficacious in selected patients.
Infiltrative Vessel Co-optive Growth Pattern Induced by IQGAP3 Overexpression Promotes Microvascular Invasion in Hepatocellular Carcinoma
Authors: Miaoling Tang, Shuxia Zhang, Meisongzhu Yang, Rongni Feng, Jinbin Lin, Xiaohong Chen, Yingru Xu, Ruyuan Yu, Xinyi Liao, Ziwen Li, Xincheng Li, Man Li, Qiliang Zhang, Suwen Chen, Wanying Qian, Yuanji Liu, Libing Song, Jun Li
Journal: Clinical Cancer Research (2024)

Microvascular invasion (MVI) is a major unfavorable prognostic factor for intrahepatic metastasis and postoperative recurrence of hepatocellular carcinoma (HCC). However, the intervention and preoperative prediction for MVI remain clinical challenges due to the absent precise mechanism and molecular marker(s). Herein, we aimed to investigate the mechanisms underlying vascular invasion that can be applied to clinical intervention for MVI in HCC.
Polo-like Kinase 1 Inhibition in <i>KRAS</i>-Mutated Metastatic Colorectal Cancer
Authors: Justin Stebbing, Andrea J. Bullock
Journal: Clinical Cancer Research (2024)

Summary: Inhibition of Polo-like kinase 1 (Plk1) is a promising new target and therapeutic strategy in metastatic colorectal cancer, especially those with KRAS mutations. New data support further development of onvansertib, and highlights the role of circulating tumor DNA in phase I clinical trials. See related article by Ahn et al., p. 2039
Cell-free DNA Concentration as a Biomarker of Response and Recurrence in HER2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy
Authors: Mark Jesus M. Magbanua, Ziad Ahmed, Rosalyn W. Sayaman, Lamorna Brown Swigart, Gillian L. Hirst, Christina Yau, Denise M. Wolf, Wen Li, Amy L. Delson, Jane Perlmutter, Paula Pohlmann, W. Fraser Symmans, Douglas Yee, Nola M. Hylton, Laura J. Esserman, Angela M. DeMichele, Hope S. Rugo, Laura J. van 't Veer
Journal: Clinical Cancer Research (2024)

Abstract Purpose: We previously demonstrated the clinical significance of circulating tumor DNA (ctDNA) in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy (NAC). Here, we compared its predictive and prognostic value with cell-free DNA (cfDNA) concentration measured in the same samples from the same patients. Experimental Design: 145 patients with hormone receptor (HR)-positive/HER2-negative and 138 triple-negative breast cancer (TNBC) with ctDNA data from a previous study were included in the analysis. Associations of serial cfDNA concentration with residual cancer burden (RCB) and distant recurrence-free survival (DRFS) were examined. Results: In TNBC, we observed a modest negative correlation between cfDNA concentration 3 weeks after treatment initiation and RCB, but none of the other timepoints showed significant correlation. In contrast, ctDNA was significantly positively correlated with RCB at all timepoints (all R &amp;gt; 0.3 and P &amp;lt; 0.05). In the HR-positive/HER2-negative group, cfDNA concentration did not associate with response to NAC, but survival analysis showed that high cfDNA shedders at pretreatment had a significantly worse DRFS than low shedders (hazard ratio, 2.12; P = 0.037). In TNBC, the difference in survival between high versus low cfDNA shedders at all timepoints was not statistically significant. In contrast, as previously reported, ctDNA at all timepoints was significantly correlated with DRFS in both subtypes. Conclusions: In TNBC, cfDNA concentrations during therapy were not strongly correlated with response or prognosis. In the HR-positive/HER2-negative group, pretreatment cfDNA concentration was prognostic for DRFS. Overall, the predictive and prognostic value of cfDNA concentration was more limited than that of ctDNA.
Dynamic optical coherence tomography and reflectance confocal microscopy of basal cell carcinoma of the nipple–areola complex
Authors: Carmen Cantisani, Alberto Taliano, Caterina Longo, Giulio Bortone, Luca Gargano, Noah Musolff, Giovanni Pellacani
Journal: British Journal of Dermatology (2024)

Journal Article Dynamic optical coherence tomography and reflectance confocal microscopy of basal cell carcinoma of the nipple–areola complex Get access Carmen Cantisani, Carmen Cantisani Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing - original draft, Writing - review & editing UOC of Dermatology, Policlinico Umberto I Hospital, Sapienza Medical School of Rome, Rome Correspondence: Carmen Cantisani. Email: carmen.cantisani@uniroma1.it Search for other works by this author on: Oxford Academic Google Scholar Alberto Taliano, Alberto Taliano Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing - original draft, Writing - review & editing UOC of Dermatology, Policlinico Umberto I Hospital, Sapienza Medical School of Rome, Rome Search for other works by this author on: Oxford Academic Google Scholar Caterina Longo, Caterina Longo Supervision, Validation Azienda Unità Sanitaria Locale - IRCCS di Reggio Emilia, Skin Cancer Center, Reggio EmiliaDermatology Department, University of Modena and Reggio Emilia, Italy Search for other works by this author on: Oxford Academic Google Scholar Giulio Bortone, Giulio Bortone Formal analysis, Investigation, Resources, Validation, Writing - original draft UOC of Dermatology, Policlinico Umberto I Hospital, Sapienza Medical School of Rome, Rome Search for other works by this author on: Oxford Academic Google Scholar Luca Gargano, Luca Gargano Data curation, Funding acquisition, Methodology, Writing - review & editing UOC of Dermatology, Policlinico Umberto I Hospital, Sapienza Medical School of Rome, Rome Search for other works by this author on: Oxford Academic Google Scholar Noah Musolff, Noah Musolff Conceptualization, Data curation, Investigation, Methodology, Project administration, Resources, Software, Visualization, Writing - original draft, Writing - review & editing UOC of Dermatology, Policlinico Umberto I Hospital, Sapienza Medical School of Rome, Rome Search for other works by this author on: Oxford Academic Google Scholar Giovanni Pellacani Giovanni Pellacani Supervision UOC of Dermatology, Policlinico Umberto I Hospital, Sapienza Medical School of Rome, Rome Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 190, Issue 6, June 2024, Page 933, https://doi.org/10.1093/bjd/ljae104 Published: 12 March 2024 Article history Received: 07 February 2024 Revision received: 03 March 2024 Accepted: 04 March 2024 Published: 12 March 2024 Corrected and typeset: 16 April 2024
Mortality Landscape of Behçet's Disease
Authors: Do-Young Kim
Journal: British Journal of Dermatology (2024)

Journal Article Accepted manuscript Mortality Landscape of Behçet's Disease Get access Do-Young Kim Do-Young Kim Department of Dermatology and Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul, Republic of Korea Corresponding author: Email:dykim@yuhs.ac https://orcid.org/0000-0002-0194-9854 Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, ljae106, https://doi.org/10.1093/bjd/ljae106 Published: 12 March 2024 Article history Received: 06 March 2024 Accepted: 08 March 2024 Published: 12 March 2024
European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission
Authors: Francois-Xavier Mahon, Markus Pfirrmann, Stéphanie Dulucq, Andreas Hochhaus, Panayiotis Panayiotidis, Antonio Almeida, Jiri Mayer, Henrik Hjorth-Hansen, Jeroen J.W.M. Janssen, Satu Mustjoki, Joaquin Martinez-Lopez, Hanne Vestergaard, Hans Ehrencrona, Katerina Machová Poláková, Ulla Olsson-Strömberg, Gert Ossenkoppele, Marc G. Berger, Gabriel Etienne, Jolanta Dengler, Tim H. Brümmendorf, Andreas Burchert, Delphine Réa, Philippe Rousselot, Franck E. Nicolini, Wolf-Karsten Hofmann, Johan Richter, Susanne Saussele, Jiri Mayer, Jaroslava Voglová, Edgar Faber, Hana Klamova, Hanne Vestergaard, Perttu Koskenvesa, Francois-Xavier Mahon, Gabriel Etienne, Marc G. Berger, Philippe Rousselot, Franck E. Nicolini, Aude Charbonnier, Laurence Legros, Delphine Réa, François Guilhot, Martine Escoffre-Barbe, Françoise Huguet, Emmanuel Gyan, Tim Henrik Brümmendorf, Cornelius Waller, Jolanta Dengler, Andreas Hochhaus, Susanne Saußele, Andreas Burchert, Volker Kunzmann, Maria N. Pagoni, Panayiotis Panayiotidis, Jeroen J.W.M. Janssen, Gert Ossenkoppele, Peter E. Westerweel, Georgine E. de Greef, Franz Gruber, Henrik Hjorth-Hansen, Antonio Almeida, Joaquin Martinez-Lopez, Kourosh Lotfi, Johan Richter, Leif Stenke, Ulla Olsson-Strömberg, Stina Söderlund
Journal: Journal of Clinical Oncology (2024)

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. The European Stop Kinase Inhibitors (EURO-SKI) study is the largest clinical trial for investigating the cessation of tyrosine kinase inhibitors (TKIs) in patients with chronic myeloid leukemia in stable deep molecular remission (DMR). Among 728 patients, 434 patients (61%; 95% CI, 57 to 64) remained in major molecular response (MMR) at 6 months and 309 patients of 678 (46%; 95% CI, 42 to 49) at 36 months. Duration of TKI treatment and DMR before TKI stop were confirmed as significant factors for the prediction of MMR loss at 6 months. In addition, the type of BCR::ABL1 transcript was identified as a prognostic factor. For late MMR losses after 6 months, TKI treatment duration, percentage of blasts in peripheral blood, and platelet count at diagnosis were significant factors in multivariate analysis. For the entire study period of 36 months, multiple logistic regression models confirmed duration of treatment, blasts, and transcript type as independent factors for MMR maintenance. In addition to the duration of treatment, transcript type as well as blasts in peripheral blood at diagnosis should be considered as important factors to predict treatment-free remission.
Prognostic Impact of Prostate-Specific Antigen at 6 Months After Radiotherapy in Localized Prostate Cancer: An Individual Patient Data Analysis of Randomized Trials
Authors: Lucia Kwak, Praful Ravi, John G. Armstrong, Veronique Beckendorf, Joseph L. Chin, Anthony V. D'Amico, David P. Dearnaley, Savino M. Di Stasi, Silke Gillessen, Himanshu Lukka, Nicolas Mottet, Pascal Pommier, Wendy Seiferheld, Matthew R. Sydes, Bertrand Tombal, Almudena Zapatero, Meredith M. Regan, Wanling Xie, Christopher J. Sweeney
Journal: Journal of Clinical Oncology (2024)

PURPOSE We sought to evaluate the prognostic impact of prostate-specific antigen (PSA) at 6 months after completion of radiotherapy (RT) in patients treated with RT alone, RT plus short-term (st; 3-6 months), and RT plus long-term (lt; 24-36 months) androgen-deprivation therapy (ADT). PATIENTS AND METHODS Individual patient data were obtained from 16 randomized trials evaluating RT ± ADT for localized prostate cancer (PCa) between 1987 and 2011. The lowest PSA recorded within 6 months after RT completion was identified and categorized as &lt; or ≥0.1 ng/mL. The primary outcomes were metastasis-free survival (MFS), PCa-specific mortality (PCSM), and overall survival (OS), from 12 months after random assignment. RESULTS Ninety-eight percent (n = 2,339/2,376) of patients allocated to RT alone, 84% (n = 4,756/5,658) allocated to RT + stADT, and 77% (n = 1,258/1,626) allocated to RT + ltADT had PSA ≥0.1 ng/mL within 6 months after completing RT. PSA ≥0.1 ng/mL was associated with lower MFS and OS and higher PCSM among patients allocated to RT ± ADT (RT – MFS: hazard ratio [HR], 2.24 [95% CI, 1.21 to 4.16]; PCSM: subdistribution hazard ratio [sHR], 1.82 [0.51 to 6.49]; OS: HR, 1.72 [0.97 to 3.05]; RT + stADT – MFS: HR, 1.27 [1.12 to 1.44]; PCSM: sHR, 2.10 [1.52 to 2.92]; OS: HR, 1.26 [1.11 to 1.44]; RT + ltADT – MFS: HR, 1.58 [1.27 to 1.96]; PCSM: sHR, 1.97 [1.11 to 3.49]; OS: HR, 1.59 [1.27 to 1.99]). Five-year MFS rates among patients allocated to RT, RT + stADT, and RT + ltADT were 91% versus 79%, 83% versus 76%, and 87% versus 74%, respectively, based on PSA &lt; or ≥0.1 ng/mL. CONCLUSION PSA ≥0.1 ng/mL within 6 months after RT completion was prognostic for lt outcomes in patients treated with RT ± ADT for localized PCa. This can be used to counsel patients treated with RT ± ADT and in guiding clinical trial design evaluating novel systemic therapies with RT + ADT as well as (de)intensification strategies.
Promoting swimming: a positive approach to public health
Authors: Michael Craig Watson, Karen E Neil
Journal: BMJ (2024)

There are around 236 000 drowning deaths worldwide each year, most of them young children. 1 The family, social, and economic toll of these losses is intolerably high and entirely preventable, 1 2 which is why we are grateful to McNally for highlighting swimming as an important but neglected area of public health.
Effect of Prior Prostate Directed Local Therapy on Response to Apalutamide in Metastatic Hormone Sensitive Prostate Cancer: A Secondary Analysis of the TITAN Study
Authors: Soumyajit Roy, Fred Saad, Shawn Malone, Neeraj Agarwal, Osama Mohamad, Scott C. Morgan, Julia Malone, Umang Swami, Angela Y. Jia, Georges Gebrael, Prateek Mendiratta, Jason R. Brown, Santosh K. Rao, Yilun Sun, Christopher J.D. Wallis, Kim N. Chi, Simon Chowdhury, Amar U. Kishan, Daniel E. Spratt
Journal: European Urology (2024)
Constructing the Framework for Disease Modification in Pulmonary Arterial Hypertension
Authors: Roham T. Zamanian, Jason Weatherald, Andrew J. Sweatt, Anna Hemnes, Moira Rashid, Mitchell A. Psotka, Harm J. Bogaard, Vinicio de Jesus Perez
Journal: American Journal of Respiratory and Critical Care Medicine (2024)

"Constructing the Framework for Disease Modification in Pulmonary Arterial Hypertension." American Journal of Respiratory and Critical Care Medicine, 209(10), pp. 1189–1195
Impact of Type 2 Diabetes and Glycated Hemoglobin Levels Within the Recommended Target Range on Mortality in Older Adults With Cognitive Impairment Receiving Care at a Memory Clinic: NCGG-STORIES
Authors: Taiki Sugimoto, Takashi Sakurai, Kazuaki Uchida, Yujiro Kuroda, Haruhiko Tokuda, Takuya Omura, Taiji Noguchi, Ayane Komatsu, Takeshi Nakagawa, Kosuke Fujita, Nanae Matsumoto, Rei Ono, Paul K. Crane, Tami Saito
Journal: Diabetes Care (2024)

To determine the impact of type 2 diabetes and glycated hemoglobin (HbA1c) levels within the recommended target range according to the Japan Diabetes Society/Japan Geriatrics Society Joint Committee on mortality in older adults with cognitive impairment.
The Cardioprotective and Anticancer Effects of SGLT2 Inhibitors
Authors: Mohamed S. Dabour, Mina Y. George, Mary R. Daniel, Anne H. Blaes, Beshay N. Zordoky
Journal: JACC CardioOncology (2024)

Sodium-glucose cotransporter-2 (SGLT2) inhibitors, originally approved for type 2 diabetes mellitus, have demonstrated efficacy in reducing cardiovascular events, particularly heart failure, in patients with and without diabetes. An intriguing research area involves exploring the potential application of SGLT2 inhibitors in cardio-oncology, aiming to mitigate the cardiovascular adverse events associated with anticancer treatments. These inhibitors present a unique dual nature, offering both cardioprotective effects and anticancer properties, conferring a double benefit for cardio-oncology patients. In this review, the authors first examine the established cardioprotective effects of SGLT2 inhibitors in heart failure and subsequently explore the existing body of evidence, including both preclinical and clinical studies, that supports the use of SGLT2 inhibitors in the context of cardio-oncology. The authors further discuss the mechanisms through which SGLT2 inhibitors protect against cardiovascular toxicity secondary to cancer treatment. Finally, they explore the potential anticancer effects of SGLT2 inhibitors along with their proposed mechanisms.